FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Annita Kolnagou

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Magnetic Resonance Imaging

Anatomy

Co-author Network

Publications

TOP 3
Christina N Kontoghiorghe; Annita Kolnagou; George J Kontoghiorghes
Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.
Annita Kolnagou; Christina N Kontoghiorghe; Yiannis Michaelides; George J Kontoghiorghes
The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
Tammy Born; Annita Kolnagou; Christina N Kontoghiorghe; Aspasia Spyrou; George J Kontoghiorghes
EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Annita Kolnagou (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christina N Kontoghiorghe; Annita Kolnagou; George J Kontoghiorghes
Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.
Expert opinion on investigational drugs 2013;22(5):591-618.
2013: Annita Kolnagou; Christina N Kontoghiorghe; Yiannis Michaelides; George J Kontoghiorghes
The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
Toxicology mechanisms and methods 2013;23(1):34-41.
2013: Tammy Born; Annita Kolnagou; Christina N Kontoghiorghe; Aspasia Spyrou; George J Kontoghiorghes
EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Toxicology mechanisms and methods 2013;23(1):11-7.
2013: Annita Kolnagou; Alexia Ioannou; Marios Kleanthous; Konstantinos Natsiopoulos; George J Kontoghiorghes
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Toxicology mechanisms and methods 2013;23(1):48-56.
2011: Eleni Konstantinou; Ioannis Pashalidis; Annita Kolnagou; George J Kontoghiorghes
Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies.
Hemoglobin 2011;35(3):237-46.
2011: Annita Kolnagou; Marios Kleanthous; George J Kontoghiorghes
Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Hemoglobin 2011;35(3):186-98.
2010: Annita Kolnagou; Marios Kleanthous; George J Kontoghiorghes
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
European journal of haematology 2010;85(5):430-8.
2010: Annita Kolnagou; George J Kontoghiorghes
Future challenges in the use of magnetic resonance imaging for the diagnosis of iron overload.
Blood transfusion = Trasfusione del sangue 2010;8(4):309-10.
2010: Annita Kolnagou; George J Kontoghiorghes
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
British journal of haematology 2010;150(4):489-90; author reply 491.
2010: George J Kontoghiorghes; Aspasia Spyrou; Annita Kolnagou
Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Hemoglobin 2010;34(3):251-64.
2010: George J Kontoghiorghes; Annita Kolnagou; ANNA SKIADA; George Petrikkos
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Hemoglobin 2010;34(3):227-39.
2010: Annita Kolnagou; George J Kontoghiorghes
Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Hemoglobin 2010;34(3):204-9.
2010: George J Kontoghiorghes; Annita Kolnagou; C-T Peng; S V Shah; A Aessopos
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
Expert opinion on drug safety 2010;9(2):201-6.
2009: George J Kontoghiorghes; Aglaia Efstathiou; Marios Kleanthous; Yiannis Michaelides; Annita Kolnagou
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Hemoglobin 2009;33(5):386-97.
2009: Annita Kolnagou; Dilek Yazman; Charalambos Economides; Eleni Eracleous; George J Kontoghiorghes
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Hemoglobin 2009;33(5):312-22.
2008: George J Kontoghiorghes; Aglaia Efstathiou; Stella Ioannou-Loucaides; Annita Kolnagou
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Hemoglobin 2008;32(1-2):217-27.
2008: Annita Kolnagou; Charalambos Economides; Eleni Eracleous; George J Kontoghiorghes
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Hemoglobin 2008;32(1-2):41-7.
2008: Annita Kolnagou; Yiannis Michaelides; Christos Kontos; Kyriacos Kyriacou; George J Kontoghiorghes
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Hemoglobin 2008;32(1-2):17-28.
2006: George J Kontoghiorghes; Annita Kolnagou
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Haematologica 2006;91(6 Suppl):ELT04.
2006: Annita Kolnagou; George J Kontoghiorghes
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Hemoglobin 2006;30(2):239-49.
2006: Annita Kolnagou; Charalambos Economides; Eleni Eracleous; George J Kontoghiorghes
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Hemoglobin 2006;30(2):219-27.
2005: George J Kontoghiorghes; Annita Kolnagou; Eleni Eracleous; Robert W Evans
Iron mobilisation from transferrin by deferiprone (L1).
British journal of haematology 2005;129(1):157.
2005: George J Kontoghiorghes; Annita Kolnagou
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Current medicinal chemistry 2005;12(23):2695-709.
2005: George J Kontoghiorghes; Eleni Eracleous; Charalambos Economides; Annita Kolnagou
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Current medicinal chemistry 2005;12(23):2663-81.
2004: Annita Kolnagou; Charis Fessas; Antonis Papatryphonas; Charalambos Economides; George J Kontoghiorghes
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia.
British journal of haematology 2004;127(3):360-1; author reply 361-2.
2004: George J Kontoghiorghes; K Pattichis; K Neocleous; Annita Kolnagou
The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Current medicinal chemistry 2004;11(16):2161-83.
2003: George J Kontoghiorghes; Annita Kolnagou
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Lancet 2003;361(9352):184.
2003: George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Drug safety : an international journal of medical toxicology and drug experience 2003;26(8):553-84.
2002: George S Douvas; Mary H May; Annita Kolnagou; George J Kontoghiorghes
Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.
Arzneimittel-Forschung 2002;52(1):45-52.
2000: George J Kontoghiorghes; K Pattichi; M Hadjigavriel; Annita Kolnagou
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Transfusion science 2000;23(3):211-23.
2000: George J Kontoghiorghes; M B Agarwal; R W Grady; Annita Kolnagou; Joannes Marx
Deferiprone for thalassaemia.
Lancet 2000;356(9227):428-9.